← Back to all signals
RESEARCH PAPER ANALYSIS

Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights.

Narrative review proposing that neurosyphilis can produce Parkinsonism via shared mechanisms—BBB disruption, dopaminergic neuronal loss, TLR-driven neuroinflammation—and summarizes diagnostic approaches and potential therapeutic repurposing (β-lactams, doxycycline) and nanoparticle-based…

PMID41926293
JournalCurrent neurovascular research
Publication Date2026-03-31
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Narrative review proposing that neurosyphilis can produce Parkinsonism via shared mechanisms—BBB disruption, dopaminergic neuronal loss, TLR-driven neuroinflammation—and summarizes diagnostic approaches and potential therapeutic repurposing (β-lactams, doxycycline) and nanoparticle-based…

WHY IT MATTERS

Research significance

Identifies actionable, translationally relevant mechanisms (BBB integrity, neuroinflammation, dopaminergic degeneration) and repurposing/delivery strategies that could inform PD-targeted therapeutic development and differential-diagnostic biomarker work, despite being a non-systematic review with…

ABSTRACT

Source abstract

INTRODUCTION: Neurosyphilis, caused by Treponema pallidum, is a complex neurological condition arising from untreated syphilis and can present with diverse manifestations, including Parkinsonism-like motor dysfunction. Its pathophysiology involves Blood-Brain Barrier (BBB) disruption, dopaminergic neuronal loss, and neuroinflammatory cascades that resemble mechanisms seen in idiopathic Parkinson's Disease (PD). METHODS: A literature review from PubMed, ScienceDirect, Scopus, and Google Scholar (2014- 2025) explored studies on neurosyphilis, dopaminergic degeneration, BBB dysfunction, neuroinflammation, diagnostics, and treatments, including antibiotics, neuroprotective agents, nanocarriers, and vaccines. A narrative synthesis was conducted due to the variation in study designs. RESULTS: The decreased BBB permeability, extracellular matrix degradation, TLR activation, reactive microglia, and neuronal cell death are mechanisms linking syphilis and idiopathic PD. Neurologists differentiate between neurosyphilis and idiopathic PD through neuroimaging and cerebrospinal fluid analysis (CSF). Treatment for neurosyphilis primarily involves penicillin, with alternatives such as ceftriaxone and doxycycline. Emerging evidence suggests that β-lactam antibiotics and nanoparticle systems targeting neuroinflammatory pathways may offer neuroprotective effects. DISCUSSION: These findings exhibit considerable mechanistic overlap between neurosyphilis and PD, particularly concerning BBB dysfunction, dopaminergic neurodegeneration, and neuroinflammation. These common pathways lead to symptoms similar to those of PD and complicate clinical manifestation. Neuroimaging and CSF analyses are still very important for making an accurate diagnosis. Further study is needed to clarify disease mechanisms and to evaluate novel therapeutic approaches. CONCLUSION: Neurosyphilis may present with Parkinsonian features due to PD-like neurodegenerative mechanisms. Early diagnosis and timely antimicrobial therapy are crucial to prevent irreversible neurological damage, while emerging neuroprotective strategies warrant further investigation.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 27 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 28 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 29 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 30 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 31 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0 32 Vitamins as Modulators of Neurodegenerative Disease Pathways: Mechanisms and Therapeutic Perspectives. Nutrients 74.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic